| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3030625 | Trends in Cardiovascular Medicine | 2010 | 7 Pages |
Abstract
Adrenergic and angiotensin receptors are prominent targets in pharmacological alleviation of cardiac remodeling and heart failure, but their use is associated with cardiodepressant side effects. Recent advances in our understanding of seven transmembrane receptor signaling show that it is possible to design ligands with “functional selectivity,” acting as agonists on certain signaling pathways while antagonizing others. This represents a major pharmaceutical opportunity to separate desired from adverse effects governed by the same receptor. Accordingly, functionally selective ligands are currently pursued as next-generation drugs for superior treatment of heart failure.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Gitte Lund Christensen, Mark Aplin, Jakob Lerche Hansen,